FCF YoY
+24.65%
OCF YoY
+24.65%
Capex Change
+0.0
FCF Conversion Δ
—
Free cash flow bridge for Relmada Therapeutics (RLMD) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $14.00M
FCF bridge breakdown for Relmada Therapeutics (RLMD) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | −$56.79M | — |
| Operating Cash Flow | $14.00M | +100.0% |
| Capital Expenditure | $0.00 | 0.0% |
| Free Cash Outflow | −$42.79M | — |
- Prior Free Cash Flow−$56.79M
- Operating Cash Flow$14.00M
- Capital Expenditure$0.00
- Free Cash Outflow−$42.79M
Identity check: drivers reconcile to ΔNI within $1.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement